BIOtechnology Applied to Renal TRansplantation With IMmunobiogram

CompletedOBSERVATIONAL
Enrollment

443

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Kidney Transplant Failure and Rejection
Interventions
DIAGNOSTIC_TEST

Immunobiogram

This is not an interventional study. However the assay being tested on the blood samples of all enrolled participants is the Immunobiogram (IMBG). IMBG is an in vitro diagnostic immunoassay which can obtain dose-response curves that describe the inhibitory effect of each immunosuppressant on immune response cells (immunologically stimulated PBMCs) in kidney transplant patients.

Trial Locations (15)

Unknown

Hospital Do Rim, Brasil

University Hospital Grenoble, Grenoble

Charité Universitätsmedizin Berlin, Berlin

Universitätsklinikum Heidelberg, Heidelberg

Fundació Puigvert, Barcelona

Hospital Clínic de Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Universitario Puerta del Mar, Cadiz

Hospital Clínico San Carlos, Madrid

Hospital Universitario 12 Octubre, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Hospital Universitario Marqués de Valdecilla, Santander

Hospital Universitario Dr. Peset, Valencia

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Biohope Scientific Solutions for Human Health, S.L.

INDUSTRY